They found that most of the non-tumoral tissue exhibited moderate immunostaining for Galectin-3 localized in both nucleus and cytoplasm and prostate cancer cells showed decrease of the expression of the Galectin-3 or not expression compared to the normal tissue. Here, LGALS3 is linked to prostate carcinoma.